Latest News

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Fina

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class...

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Pote

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Unins...

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episo...

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic M

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva to Present at the Jefferies London Healthcare Conference

Teva to Present at the Jefferies London Healthcare Conference

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance a...

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and In

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Reveal...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing D

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demon...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrat

Teva Statement on European Commission Decision; Company to Appeal

Teva Statement on European Commission Decision; Company to Appeal

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-ae...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn),

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candida...

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide ac...

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate